Factors affecting functional outcome after autologous skeletal myoblast transplantation - PubMed (original) (raw)
Factors affecting functional outcome after autologous skeletal myoblast transplantation
B Pouzet et al. Ann Thorac Surg. 2001 Mar.
Abstract
Background: This study assessed the extent to which the initial degree of functional impairment and the number of injected cells may influence the functional improvement provided by autologous skeletal myoblast transplantation into infarcted myocardium.
Methods: One week after left coronary artery ligation, 44 rats received into the infarcted scar, autologous skeletal myoblasts expanded in vitro for 7 days (mean, 3.5 x 10(6), n = 21), or culture medium alone (controls, n = 23). Left ventricular function was assessed by two-dimensional echocardiography.
Results: When transplanted hearts were stratified according to their baseline ejection fraction, a significant improvement occurred at 2 months in the less than 25% (from 21.4% to 37%), 25% to 35% (from 29% to 43.8%), and in the 35% to 40% (from 37.2% to 41.7%) groups, compared to controls (p = 0.048, 0.0057, and 0.034, respectively), but not in the more than 40% stratum. A significant linear relationship was found between the improvement in ejection fraction and the number of injected myoblasts, both at 1 and 2 months after transplantation (p < 0.0001).
Conclusions: Autologous myoblast transplantation is functionally effective over a wide range of postinfarct ejection fractions, including in the sickest hearts provided that they are injected with a sufficiently high number of cells.
Comment in
- Cellular myoplasty: what are we really trying to achieve?
Gorman RC, Gorman JH 3rd. Gorman RC, et al. Ann Thorac Surg. 2002 Jan;73(1):342-3. doi: 10.1016/s0003-4975(01)03255-6. Ann Thorac Surg. 2002. PMID: 11834052 No abstract available.
Similar articles
- Is skeletal myoblast transplantation clinically relevant in the era of angiotensin-converting enzyme inhibitors?
Pouzet B, Ghostine S, Vilquin JT, Garcin I, Scorsin M, Hagège AA, Duboc D, Schwartz K, Menasché P. Pouzet B, et al. Circulation. 2001 Sep 18;104(12 Suppl 1):I223-8. doi: 10.1161/hc37t1.094593. Circulation. 2001. PMID: 11568060 - Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function.
Scorsin M, Hagège A, Vilquin JT, Fiszman M, Marotte F, Samuel JL, Rappaport L, Schwartz K, Menasché P. Scorsin M, et al. J Thorac Cardiovasc Surg. 2000 Jun;119(6):1169-75. doi: 10.1067/mtc.2000.104865. J Thorac Cardiovasc Surg. 2000. PMID: 10838534 - Intramyocardial transplantation of autologous myoblasts: can tissue processing be optimized?
Pouzet B, Vilquin JT, Hagège AA, Scorsin M, Messas E, Fiszman M, Schwartz K, Menasché P. Pouzet B, et al. Circulation. 2000 Nov 7;102(19 Suppl 3):III210-5. doi: 10.1161/01.cir.102.suppl_3.iii-210. Circulation. 2000. PMID: 11082389 - Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia-inducible factor 1alpha.
Azarnoush K, Maurel A, Sebbah L, Carrion C, Bissery A, Mandet C, Pouly J, Bruneval P, Hagège AA, Menasché P. Azarnoush K, et al. J Thorac Cardiovasc Surg. 2005 Jul;130(1):173-9. doi: 10.1016/j.jtcvs.2004.11.044. J Thorac Cardiovasc Surg. 2005. PMID: 15999059 - [Transplantation of autologous skeletal myoblasts in ischemic cardiac insufficiency].
Pouzet B, Hagège AA, Vilquin JT, Desnos M, Duboc D, Marolleau JP, Menashé P. Pouzet B, et al. J Soc Biol. 2001;195(1):47-9. J Soc Biol. 2001. PMID: 11530499 Review. French.
Cited by
- RGDfK-Peptide Modified Alginate Scaffold for Cell Transplantation and Cardiac Neovascularization.
Sondermeijer HP, Witkowski P, Seki T, van der Laarse A, Itescu S, Hardy MA. Sondermeijer HP, et al. Tissue Eng Part A. 2018 May;24(9-10):740-751. doi: 10.1089/ten.TEA.2017.0221. Epub 2017 Nov 13. Tissue Eng Part A. 2018. PMID: 28938862 Free PMC article. - Sca-1+ stem cell survival and engraftment in the infarcted heart: dual role for preconditioning-induced connexin-43.
Lu G, Haider HK, Jiang S, Ashraf M. Lu G, et al. Circulation. 2009 May 19;119(19):2587-96. doi: 10.1161/CIRCULATIONAHA.108.827691. Epub 2009 May 4. Circulation. 2009. PMID: 19414636 Free PMC article. - Mesenchymal stem cell delivery into rat infarcted myocardium using a porous polysaccharide-based scaffold: a quantitative comparison with endocardial injection.
Le Visage C, Gournay O, Benguirat N, Hamidi S, Chaussumier L, Mougenot N, Flanders JA, Isnard R, Michel JB, Hatem S, Letourneur D, Norol F. Le Visage C, et al. Tissue Eng Part A. 2012 Jan;18(1-2):35-44. doi: 10.1089/ten.TEA.2011.0053. Epub 2011 Sep 21. Tissue Eng Part A. 2012. PMID: 21770864 Free PMC article. - Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells.
Tedesco FS, Dellavalle A, Diaz-Manera J, Messina G, Cossu G. Tedesco FS, et al. J Clin Invest. 2010 Jan;120(1):11-9. doi: 10.1172/JCI40373. J Clin Invest. 2010. PMID: 20051632 Free PMC article. Review. - Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage.
Hamamoto H, Gorman JH 3rd, Ryan LP, Hinmon R, Martens TP, Schuster MD, Plappert T, Kiupel M, St John-Sutton MG, Itescu S, Gorman RC. Hamamoto H, et al. Ann Thorac Surg. 2009 Mar;87(3):794-801. doi: 10.1016/j.athoracsur.2008.11.057. Ann Thorac Surg. 2009. PMID: 19231391 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical